Chinetti-Gbaguidi G, Fruchart J-C, Staels B
UR 545 INSERM, Institut Pasteur de Lille, Université de Lille 2, Lille, France.
Biomarkers. 2005 Nov;10 Suppl 1:S30-6. doi: 10.1080/13547500500216702.
The metabolic syndrome is defined as the clustering of cardiovascular risk factors, such as glucose intolerance, hyperinsulinemia, dyslipidemia, coagulation disturbances and hypertension. Activators of the nuclear receptors peroxisome proliferator-activated receptors (PPARs) modulate several of the metabolic risk factors pre-disposing to atherosclerosis. Fibrates are hypolipidemic drugs operating through activation of PPARalpha, whereas glitazones are insulin sensitizers activating PPARgamma. In addition, these drugs exert pleiotropic and anti-inflammatory actions. This review will focus on the different effects of fibrates and glitazones, as measured by biomarker modulation, on the development of atherosclerosis and cardiovascular disease.
代谢综合征被定义为心血管危险因素的聚集，如葡萄糖不耐受、高胰岛素血症、血脂异常、凝血紊乱和高血压。核受体过氧化物酶体增殖物激活受体（PPARs）的激活剂可调节多种易导致动脉粥样硬化的代谢危险因素。贝特类药物是通过激活PPARα发挥作用的降血脂药物，而格列酮类药物是激活PPARγ的胰岛素增敏剂。此外，这些药物还具有多效性和抗炎作用。本综述将重点关注贝特类药物和格列酮类药物通过生物标志物调节所测得的对动脉粥样硬化和心血管疾病发展的不同影响。
